Breast cancer precursor test firm hopes IPO will toss up $6m new funds
This article was originally published in Clinica
Executive Summary
Seattle, Washington-based Atossa Genetics is looking to raise around $6 million through an IPO on the Nasdaq to fund commercialisation of its diagnostic tests, designed to detect precursors to breast cancer.